- Home >
- Publications >
- HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
Authors
Rania El‐Botty, Sophie Vacher, Juliette Mainguené, Adrien Briaux, Sabrina Ibadioune, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Léa Huguet, Laura Sourd, Ludivine Morriset, Sophie Château‐Joubert, Thierry Dubois, Virginie Maire, Rosette Lidereau, Audrey Rapinat, David Gentien, Florence Coussy, Ivan Bièche, Elisabetta Marangoni
Abstract
Triple negative breast cancers (TNBCs) represent 15–20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines combined with cyclophosphamide (AC) followed by taxanes, in the neo‐adjuvant or adjuvant setting. This work aimed to identify predictive biomarkers of AC response in patient‐derived xenograft (PDX) models of TNBC and to validate them in the clinical setting. By gene and protein expression analysis of 39 PDX with different responses to AC, we found that high expression of
Members

DAVID GENTIEN
Ingénieur de recherche
VIRGINIE MAIRE
Ingénieur d'études
LAURA SOURD
Ingénieur d'études